logo-loader
viewScancell Holdings PLC

Scancell-led team short-listed for award

The Cancer Research UK Grand Challenge is a prestigious award that brings with it significant funding

woman at microscope
The scientists are aiming to identify the most effective treatments for patients with most strains of the disease

A team led by Scancell Holdings Plc’s (LON:SCLP) chief scientific officer that is pioneering a vaccine-led approach to tackling tumours has been shortlisted for  a £20mln award.

Professor Lindy Durrant is teaming up with researchers from Genentech, BioNtech and ISA Pharmaceuticals to develop Project Blueprint.

The scientists are aiming to identify the most effective treatments for patients with most strains of the disease.

However the focus, at least initially, will be on head, neck lung, and pancreatic cancers as well as, glioblastoma - all of which currently have a poor prognosis.

Modi-3 may play a role

As part of the programme, Durrant’s team will consider whether Scancell’s Modi-3 product has a role to play.

Project Blueprint has been shortlisted for the Cancer Research UK Grand Challenge, a prestigious award that brings with it £20mln of funding.

Last year four teams won financial backing from the charity.

READ: Scancell eyeing investigational new drug application for SCIB1 in first half

Durrant said: “This brings us one step closer to delivering our cancer vaccine blueprint. 

“We believe this approach will provide an effective, novel therapy and facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer. 

“Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space."

Quick facts: Scancell Holdings PLC

Price: 5.05 GBX

LSE:SCLP
Market: LSE
Market Cap: £23.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly. CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing...

on 5/9/19

2 min read